Browsing by Author "Symeonidis, A."
Now showing items 1-6 of 6
-
99mTc sestamibi as a prognostic factor of response to first-line therapy and outcome in patients with malignant lymphoma
Spyridonidis, T. J.; Matsouka, P.; Symeonidis, A.; Savvopoulos, C.; Vassilakos, P. J.; Apostolopoulos, D. J. (2013)INTRODUCTION: Resistance to chemotherapy poses a major problem in cancer patients. Although of multifactorial origin, some of the implicated mechanisms also interfere with Tc-MIBI uptake and retention in cancer cells. The ... -
Efficacy of Interferon A-2b Monotherapy in B-Thalassemics with Chronic Hepatitis C
Kalafateli, M.; Kourakli, A.; Gatselis, N.; Lambropoulou, P.; Thomopoulos, K.; Tsamandas, A.; Christofidou, M.; Zachou, K.; Jelastopoulou, E.; Nikolopoulou, V.; Symeonidis, A.; Dalekos, G. N.; Lambropoulou-Karatza, C.; Triantos, C. (2015)Background & Aims: Monotherapy with standard or pegylated interferon (PegIFN) remains the first-line treatment for HCV infection in patients with thalassemia major (beta TM), although its long-term impact is still unknown. ... -
Long term efficacy of Interferon a-2b/Peg-Iinterferon a-2b monotherapy in b-thalassemics with chronic hepatitis C
Triantos, C. K.; Kourakli, A.; Gatselis, N.; Kalafateli, M.; Lambropoulou, P.; De Lastic, A. L.; Thomopoulos, K.; Tsamandas, A.; Christofidou, M.; Jelastopulu, E.; Nikolopoulou, V.; Symeonidis, A.; Dalekos, G. N.; Labropoulou-Karatza, C. C. (2013) -
Overexpression of phosphorylated p27(Kip1) at threonine 187 may predict outcome in aggressive B-cell lymphomas
Sirinian, C.; Symeonidis, A.; Giannakoulas, N.; Zolota, V.; Melachrinou, M. (2011)Phosphorylation of p27<SUKip1</SU at threonine 187 (pThr187-p27<SUKip1</SU) occurs frequently in the development of human tumors, directing protein polyubiquitination and subsequent proteasomal degradation. We investigated ... -
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Katodritou, E.; Terpos, E.; Kelaidi, C.; Kotsopoulou, M.; Delimpasi, S.; Kyrtsonis, M. C.; Symeonidis, A.; Giannakoulas, N.; Stefanoudaki, A.; Christoulas, D.; Chatziaggelidou, C.; Gastari, V.; Spyridis, N.; Verrou, E.; Konstantinidou, P.; Zervas, K.; Dimopoulos, M. A. (2014)Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety ... -
Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group
Symeonidis, A.; Galanopoulos, A.; Hatzimichael, E.; Kouraklis, A.; Korantzis, I.; Kartasis, Z.; Giannakoulas, N.; Michali, E.; Kokkini, G.; Vagia, M.; Kotsopoulou, M.; Pappa, V.; Papadaki, E.; Bourantas, K.; Matsouka, P.; Anagnostopoulos, N.; Zoumbos, N.; Hellenic, M. D. S. Study Grp (2009)